Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(66.7%)

N/A

1(33.3%)

3Total

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06709274Not ApplicableNot Yet Recruiting

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Role: collaborator

NCT06083779Unknown

Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics

Role: collaborator

NCT05778955Unknown

Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma

Role: collaborator

NCT05693987Unknown

Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Prospective Study)

Role: collaborator

NCT05693974Unknown

Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study)

Role: collaborator

NCT05594381Phase 2Unknown

A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.

Role: collaborator

NCT05174156Phase 2Unknown

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Role: collaborator

NCT05269056Unknown

Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics

Role: collaborator

All 8 trials loaded